Core Insights - The National Medical Products Administration (NMPA) has accepted a new drug application for the first-in-class dual antibody ADC drug, iza-bren, developed by BaiLi Tianheng, aimed at treating recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after failure of PD-1/PD-L1 monoclonal antibody combined with platinum-based chemotherapy [1][2] - The application is based on positive results from a Phase III clinical trial, which met both primary endpoints of progression-free survival (PFS) and overall survival (OS) in a pre-specified interim analysis [1] - Esophageal cancer has a significant global burden, with approximately 510,000 new cases and 445,000 deaths annually, and China accounts for about 224,000 new cases, representing 43.8% of the global total [1] Group 1 - Iza-bren has shown anti-tumor activity, safety, and efficacy in a Phase Ib clinical study published in the journal Nature Medicine [2] - Currently, over 40 clinical studies are ongoing for iza-bren in China and the U.S., including 10 registration Phase III studies in China and 3 global pivotal registration studies [2] - Seven indications for iza-bren have been included in the breakthrough therapy designation list by the CDE, and one indication has been designated as breakthrough therapy by the FDA [2] Group 2 - There are currently only 10 new biological drugs approved for esophageal cancer treatment globally, with no ADCs approved yet [3] - If approved, BL-B01D1 will become the first ADC drug for the treatment of esophageal cancer worldwide [3]

Group 1 - The National Medical Products Administration (NMPA) accepted the market application for the first-class new drug BL-B01D1, which is indicated for recurrent or metastatic esophageal squamous cell carcinoma that has failed previous PD-1/PD-L1 monoclonal antibody combined with platinum-based chemotherapy [1] - BL-B01D1 (Iza-bren) is a globally innovative dual-antibody ADC that blocks signals from EGFR and HER3 to tumor cells, inhibiting their proliferation and survival [1] - The drug's mechanism includes antibody-mediated endocytosis, which releases therapeutic payloads that induce genotoxic stress, ultimately leading to tumor cell death [1] Group 2 - In December 2023, the company entered into an exclusive licensing and collaboration agreement with Bristol-Myers Squibb (BMS) for the global development and commercialization of Iza-bren [2] - BMS will pay the company an upfront fee of $800 million, along with two milestone payments of $250 million each; additional payments could reach up to $7.1 billion based on development, registration, and sales milestones [2] - The total potential deal value could reach $8.4 billion, setting a record for the highest total price for a single drug licensing agreement in the ADC field [2] - Currently, there are only 10 biopharmaceutical new drugs approved for esophageal cancer treatment globally, with no ADCs approved yet; if approved, BL-B01D1 will be the first ADC for esophageal cancer treatment [2]

Investment Rating - The report maintains an "Outperform" rating for several companies, including Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical Group, 3SBio, Sichuan Kelun Pharmaceutical, and Jiangsu Nhwa Pharmaceutical [6][7]. Core Insights - The annual J.P. Morgan Healthcare Conference concluded successfully, with positive information from global pharmaceutical companies, including new pipeline disclosures and major deals. The report highlights the high prosperity in the innovative drug sector and recommends continuous investment in innovative drugs and the industry chain [25][26]. - The A-Shares pharmaceutical sector underperformed the market in the third week of January 2026, with the Shanghai Composite Index falling by 0.4% and the SW Pharmaceutical and Biological sector declining by 0.7% [8][27]. - The Hong Kong stock pharmaceutical sector performed in line with the market, while the U.S. pharmaceutical sector underperformed. The Hang Seng Healthcare index increased by 2.4%, and the S&P 500 Healthcare Select Sector decreased by 1.1% [28]. Summary by Sections Section 1: Continuous Recommendation of Innovative Drugs and Industry Chain - The report emphasizes the high prosperity of innovative drugs and maintains overweight ratings for key pharmaceutical companies. It also recommends Biopharma/Biotech companies with promising pipelines and volume increases, as well as CXO and upstream companies benefiting from innovation [6][25]. Section 2: A-Shares Pharmaceutical Sector Performance - In the third week of January 2026, the A-Shares pharmaceutical sector's performance was ranked 17th among Shenwan primary industries, with a decline of 0.7%. The medical service sub-sector showed a positive performance of +3.3% [8][12][27]. Section 3: Hong Kong and U.S. Pharmaceutical Sector Performance - The Hong Kong pharmaceutical sector performed similarly to the market, while the U.S. sector underperformed. Notable gainers in the U.S. included MODERNA (+22%) and QUEST DIAGNOSTICS (+9%), while major decliners included BIOGEN (-12%) and BOSTON SCIENTIFIC (-10%) [28].

Core Viewpoint - OAPIII (HK) Limited plans to reduce its stake in Sichuan Baili Tianheng Pharmaceutical Co., Ltd. by up to 4.13 million shares, representing 1% of the company's total share capital, due to its own funding needs [1] Group 1 - OAPIII (HK) Limited currently holds 28,527,171 shares in the company, which accounts for 6.91% of the total share capital [1] - The shares to be sold were acquired prior to the company's initial public offering and will be released from restrictions on January 8, 2024, allowing them to be traded [1]

Group 1: Target Price Increases - The companies with the highest target price increases from January 12 to January 18 are Baili Tianheng, Hunan YN, and Huali Technology, with target price increases of 319.47%, 85.81%, and 58.27% respectively, belonging to the chemical pharmaceuticals, battery, and entertainment products industries [1][2]. Group 2: Broker Recommendations - A total of 191 listed companies received broker recommendations during the same period, with Dongpeng Beverage receiving 9 recommendations, and Pudong Development Bank receiving 8 recommendations [3][4]. - The top recommended companies include Dongpeng Beverage, Pudong Development Bank, and Guizhou Moutai, with respective recommendations from 9, 8, and 7 brokers [3][4]. Group 3: Rating Adjustments - Four companies had their ratings upgraded, including Jiayuan Technology from "Hold" to "Buy" by Tianfeng Securities, and Dike Co. from "Hold" to "Strong Buy" by CMB [5]. - One company, Shaanxi Energy, had its rating downgraded from "Buy" to "Hold" by Guotou Securities [6]. Group 4: First Coverage - During the same period, 60 instances of first coverage were reported, with companies like Chuanjin Nuo and Dongyangguang receiving "Hold" ratings from Guotai Junan Securities [7]. - Other companies receiving first coverage include Qiaoyin Co. with a "Buy" rating from Guosheng Securities, and Yubang Power with a "Buy" rating from Zheshang Securities [7].

Group 1 - The core viewpoint of the article highlights significant target price increases for certain companies, with Baile Tianheng leading at a 319.47% increase, followed by Hunan Yuneng at 85.81% and Huali Technology at 58.27% [1] - The companies with the highest target price increases belong to the chemical pharmaceuticals, battery, and entertainment products industries [1] - A total of 191 listed companies received broker recommendations during the period from January 12 to January 18, with Dongpeng Beverage receiving the most recommendations at 9, followed by Pudong Development Bank with 8, and Chao Hong Ji, Changjiang Electric Power, and Kweichow Moutai each receiving 7 [1]

Economic Information - Several smartphone manufacturers, including Xiaomi, OPPO, vivo, and Transsion, have lowered their annual shipment forecasts, with Xiaomi and OPPO reducing by over 20%, vivo by nearly 15%, and Transsion to below 70 million units [2] - Silver prices have surged over 50% in one month and over 150% in six months, impacting the photovoltaic industry, which consumes a significant amount of silver. The cost of raw materials for solar cells has increased by nearly 20% due to rising silver prices [2] - The company Xibei is expected to incur cumulative losses exceeding 600 million yuan from September 2025 to March 2026, leading to the closure of 102 stores, accounting for 30% of its total outlets [2] Company Alerts - Shenghong Technology anticipates a net profit increase of 260%-295% year-on-year for 2025, although Q4 performance fell short of expectations [4] - Cambridge Technology expects a net profit increase of 51%-67% year-on-year for 2025, with Q4 results also below expectations [4] - Multiple companies, including Weimait and Youyan Silicon, have announced plans to reduce their shareholdings by up to 4.98% and 3% respectively [4][11] Overseas Alerts - The three major U.S. stock indices collectively declined last Friday, with the Nasdaq China Golden Dragon Index dropping by 1.15%. Notable declines were seen in Chinese stocks such as Alibaba and JD.com [5] - The European Union is considering imposing tariffs on U.S. goods worth 93 billion euros in response to U.S. tariffs on eight European countries, which could take effect on February 6 if no agreement is reached [5]

Core Viewpoint - The article discusses the current state of the A-share market, highlighting the volatility and the significant net redemption of stock ETFs, indicating a shift in investor sentiment and market dynamics [14][44]. Market Overview - A-share market experienced a significant net redemption of stock ETFs amounting to 114.83 billion yuan, the largest in 13 months, contrasting with the previous week's net subscription of 17.145 billion yuan [14]. - The market sentiment has shown signs of overheating, with the Morgan Stanley A-share sentiment index surpassing the 78 threshold, reaching 93% on January 12, 2026 [17]. - The article notes that the market is expected to remain volatile in the coming week, reflecting the previous structural overheating [17]. Investment Strategies - Analysts suggest that despite short-term regulatory impacts, the overall market trend remains upward, with a focus on sectors expected to perform well during the upcoming earnings season [18]. - The article emphasizes the importance of focusing on companies with strong earnings growth potential, particularly in technology and advanced manufacturing sectors [23]. Sector Performance - The article highlights that the computer sector attracted the most capital inflow, with a net inflow of 36.184 billion yuan, followed by electronics and media sectors [47]. - Conversely, the defense, non-bank financials, and banking sectors experienced significant net outflows [44]. Industry Insights - The semiconductor sector is noted for its positive outlook, with expectations of continued price increases in memory chips, projected to rise by 55%-60% in Q1 2026 [29]. - The article also mentions the ongoing developments in the aerospace sector, with companies like China Aerospace Technology Group making progress in commercial rocket launches [24]. Economic Indicators - The article reports that China's total electricity consumption is expected to exceed 10 trillion kilowatt-hours by 2025, marking a significant milestone in global energy consumption [36]. - The article also discusses the anticipated increase in prices for various materials, including passive components and refrigerants, driven by rising demand and supply constraints [30][31].

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical sector [6][26]. Core Insights - The report emphasizes the continuous recommendation of innovative pharmaceuticals and medical devices, highlighting the high growth potential in the sector. It maintains "Overweight" ratings for companies such as Heng Rui Medicine, Hansoh Pharmaceutical, Sanofi, Kelun Pharmaceutical, and Enhua Pharmaceutical. It also recommends Biopharma/Biotech companies like Kelun Biotech, BeiGene, and others, as well as CXO and upstream pharmaceutical companies [6][3]. Summary by Sections 1. Continuous Recommendation of Innovative Pharmaceuticals and Medical Devices - The report highlights the high growth potential of innovative drugs and recommends several companies for investment, including Heng Rui Medicine, Hansoh Pharmaceutical, Sanofi, Kelun Pharmaceutical, and Enhua Pharmaceutical. It also suggests Biopharma/Biotech companies like Kelun Biotech, BeiGene, and others, as well as CXO and upstream pharmaceutical companies [6][7]. 2. A-share Pharmaceutical Sector Performance - In the third week of January 2026, the A-share pharmaceutical sector underperformed the broader market, with the Shanghai Composite Index declining by 0.4% and the SW Pharmaceutical and Biotech index falling by 0.7% [8][11]. 3. Hong Kong and US Market Performance - The Hong Kong pharmaceutical sector performed in line with the market, while the US pharmaceutical sector underperformed. In the same week, the Hang Seng Healthcare index rose by 2.4%, and the S&P 500 healthcare sector fell by 1.1% [19][20].

Industry Trends - Goldman Sachs' "2025 Global E-commerce Handbook" suggests Chinese sellers focus on ASEAN, Latin America, and the EU, as global e-commerce growth slows[1] - China's direct investment in South Africa is projected to reach $13.21 billion in 2024, shifting from traditional infrastructure to consumer goods and renewable energy[1] - Chinese automotive global market share is expected to reach 38%, with overseas sales potentially hitting 15%-20% by 2030[1] - By 2025, China's outbound model is expected to shift from single-point sales to systematic capability output, enhancing user shopping experiences[1] Top Brand News - Genki Forest has entered over 40 countries, emphasizing brand value and cultural attitudes rather than low prices[10] - Sweet Tea has opened over 200 overseas stores in two years, focusing on balancing global standards with local operations[11] - INTO YOU's overseas sales have surpassed 150 million yuan, marking a shift from product output to brand output in the beauty sector[12] - Xiangpiaopiao plans to invest $38 million in Thailand to expand in Southeast Asia amid declining domestic revenue[14]